06
May
Platinum resistant ovarian cancer remains a serious unmet medical need as treatment options are limited and response rates to these treatments are low. Other treatment modalities have tested in this setting with discouraging results.
Belinostat was given daily for 5 days with carboplatin on day 3.
Platinum resistant ovarian cancer. Platinum resistant ovarian cancer remains a serious unmet medical need as treatment options are limited and response rates to these treatments are low. The mechanisms of chemoresistance are unclear and resistance prediction methods are still evolving. Epithelial ovarian cancer (eoc) is the most lethal gynecological cancer.
Platinum resistant ovarian cancer is an invariably fatal disease. It is initially responsive to cisplatin and carboplatin, two dna damaging agents used in first line therapy. Primary ovarian cancer but resistant to platinum.
Treatment of platinum refractory or resistant ovarian cancer. However, this definition ignores the heterogeneity. Hamilton says combinations of chemotherapy with antiangiogenesis drugs, including vegf inhibitors such as bevacizumab (avastin), are being investigated in this setting.
However, almost invariably, patients relapse with a tumor resistant to subsequent treatment with platinum containing drugs. With the frĪ± protein being overexpressed in. 1 this designation is typically granted to potential new therapy options for patient populations with an unmet medical need, with investigators noting the significant treatment.
Belinostat was given daily for 5 days with carboplatin on day 3. Report the results of a randomised phase 2 trial of the efficacy and safety of adding sorafenib (an oral. My mother is suffering from advance stage recurrent aggressive platinum resistant ovarian cancer with nodules at multiple positions in stomach from liver to parts of colon.
Other treatment modalities have tested in this setting with discouraging results. The management strategy revolves around preservation of performance status and well being with current approach involving sequential single agent chemotherapy offering the best.